Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling
Nakamura I, Zakharia K, Banini BA, Mikhail DS, Kim TH, Yang JD, Moser CD, Shaleh HM, Thornburgh SR, Walters I, Roberts LR. Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. PLOS ONE 2014, 9: e92273. PMID: 24710173, PMCID: PMC3977817, DOI: 10.1371/journal.pone.0092273.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor receptorHuman hepatic stellate cellsBile duct ligationLiver fibrosisStellate cell activationPlatelet-derived growth factorCell activationHuman hepatic stellate cell activationChronic thioacetamide administrationHepatic stellate cell activationInhibition of VEGFREndothelial growth factor receptorChronic carbon tetrachlorideNovel therapeutic approachesHepatic stellate cellsStellate cell proliferationSmooth muscle actinDifferent animal modelsLX-2 human hepatic stellate cellsGrowth factor receptorHepatic fibrosisBrivanibDuct ligationLiver cancerTherapeutic approaches